skip to Main Content

AIM Market ‘Straight Take Five’: A choppy day for Bowleven


The AIM market has spent the day modestly into positive territory with the all-share index closing a little over 3 points higher at 968.08

  • Aura Energy +20%
  • Eve Sleep +18%
  • ImmuPharma -20%
  • Kodal Minerals -22%

Biggest AIM risers

News of an AUD250,000 loan was sufficient to spark fresh interest in Aura Energy [LON:AURA] during the session, driving the share price significantly higher as a result. The money is earmarked for general corporate purposes but even this modest liquidity injection has been sufficient to bolster sentiment.

This morning’s announcement that Octopus Investments  has increased their stake in Eve Sleep [LON:EVE] was sufficient to see shares in the mattress maker take off. The market ended up in auction off the back of the news, with the price pushing out to a 12 month high as a result.

Biggest AIM fallers

Shares in ImmuPharma [LON:IMM] slumped this morning off the back of news of a £6.5m placing. The 20% fall can however largely be offset against the dilution effect of the new issue.

Kodal Minerals [LON:KOD] are back in focus, although reversing some of yesterday’s bumper gains. A TR-1 showed that Jarvis sold down a significant tranche of stock yesterday so despite that MoU, at least some are happy to draw a line at this point.

Notable mention

Bowleven [LON:BLVN] had a choppy day, breaking into positive territory in the early part of the session before retreating to finish almost 12% lower. There’s no news behind the move although the longer term share price shows a recovery from the lows in March – even if the stock is well below its 2018 levels.

About this column

The AIM Straight Take is designed to cut through the hyperbole and summarise the facts of what has been driving share prices on London’s junior market. The report is currently published daily at 8am, with an intra-day update possible should demand warrant it. We would like to hear your thoughts on our new daily column. Feel free to post any feedback in the comments section below or send The Armchair Trader team an email directly to


Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top